The National University Biotechnology Regional Transfer and Transformation Center (Suzhou, Jiangsu) and Chinese tech giant Huawei jointly held an event in SIP on June 20, aiming to facilitate industry-university-research cooperation in commercializing innovative biomedical technologies.
The event was the seventh of the BioMatch Series sponsored by the center for the purpose of promoting transfer and transformation of biomedical technologies from universities across the country.
The event encompassed an introduction to the center’s service system, including its proof of concept (POC) service, and SIP’s ecosystem for transfer and transformation of outstanding scientific and technological research outcomes.
Huawei and Insilico Medicine, a biotech company that uses generative artificial intelligence and robotics to discover and develop new drugs for various indications, shared cases of their explorations and practices in driving innovative application of AI technology in the medical sector.
Ten R&D projects from universities and colleges in Shanghai, Shandong, Suzhou and other places, which are designed to support drug discovery, clinical trials, medical product manufacturing, and diagnosis and treatment, were presented at the event.
June 20, 2025
